Le Lézard
Classified in: Health, Science and technology, Business
Subjects: NPT, JVN, FVT

BioMatrix Specialty Pharmacy Partners With The National Hemophilia Foundation And Audaire Health To Improve Care For Patients With Bleeding Disorders


WESTON, Fla., Dec. 3, 2018 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today participation in a pilot program with the National Hemophilia Foundation (NHF) and Audaire Health Inc (Audaire) focused on reducing administrative burden, increasing patient adherence, and lowering health care costs.  Pilot participants include a small group of select pharmacies and Hemophilia Treatment Centers (HTCs) who will utilize Audaire's innovative data tracking tool demonstrating how the system can reduce cost of care and improve outcomes. Andrew Berg, CEO at Audaire asserts, "We are thrilled to announce our partnership with NHF and BioMatrix. It's a pleasure to find two partners as dedicated to simplifying the patient experience as we are. Our goal was to find pharmacy partners who value transparency, accountability, and driving better patient outcomes. BioMatrix is most definitely that partner."

BioMatrix SpRx Logo (PRNewsfoto/BioMatrix SpRx)

The Audaire Platform allows patients to instantly record infusions by utilizing their smart phone (at home or on the go) or a small electronic device kept in the home. The HIPAA-compliant system offers treatment reminders and passive logging capabilities that instantly transmit infusions to the patient's care team.  This "real time" reporting provides opportunities for early intervention, preventing unnecessary and costly emergency room visits and/or hospitalizations. The Audaire Platform is unique in comparison to other logging devices. The system provides a nearly passive data input solution designed to ease reporting burden for patients and pharmacy providers. By capturing multiple data points including prescription, dispensation, pharmacy/clinic touch points, reported bleeds and other medication administration information, the Audaire Platform provides more robust capabilities than current logging systems. "NHF believes that following prescribed treatments is a key to lowering costs and improving quality of life for people with bleeding disorders," said Val D. Bias, CEO of the National Hemophilia Foundation. "We hope this program can make a real difference in people's lives."

"BioMatrix has a history of leveraging unique digital health technology producing positive outcomes for patients and reducing healthcare costs," BioMatrix Chief Clinical Officer Marc Stranz shares. "This program demonstrates our commitment to providing the tools and support that make managing a chronic condition easier." Data from the pilot will be evaluated to identify the number of meaningful interventions resulting in cost reductions and or avoidance, changes in patient adherence and reporting rates, and improvements in assay and inventory management processes. The program is limited to patients on service with providers participating in the pilot. Initial findings will be shared at relevant industry symposia in 2019.  

About BioMatrix Specialty Pharmacy
BioMatrix Specialty Pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes: BiologicTx, Decillion Healthcare, Elwyn Pharmacy Group, Factor Support Network, Matrix Health, and Medex BioCare.

About the National Hemophilia Foundation
Established in 1948, National Hemophilia Foundation (NHF) is a national nonprofit patient advocacy organization dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research.  NHF is a leader in supporting innovative solutions to help people with bleeding disorders and their families manage their disorder and improve their quality of life.

About Audaire Health
Audaire Health Inc (Audaire) is a healthcare technology company that focuses on facilitating transparency and accountability between payer, provider, pharmacy and patient. On the front end, Audaire's patent pending platform allows patients to seamlessly log medication adherence and exacerbations in real time. On the back end, all stakeholders (payers, providers, pharmacies) have real time insight into patient behavior, physician behavior and pharmacy dispensations. The end result is more informed providers, better performing pharmacies, and better patient outcomes. 

 

Media Contacts


BioMatrix:          

Tara Marchese, Corporate Director of Marketing


Tel:  954-908-7636


Email:  [email protected]

 

SOURCE BioMatrix Specialty Pharmacy


These press releases may also interest you

at 16:35
American States Water Company announced today that the company intends to release its first quarter ended March 31, 2024 financial results after the market closes on Tuesday, May 7, 2024. Robert Sprowls, president and chief executive officer, and...

at 16:35
IDEX Corporation today announced its financial results for the three-month period ended March 31, 2024. "Our IDEX teams delivered solid results in the first quarter, expanding margins within our Fluid & Metering Technologies and Fire & Safety /...

at 16:35
The Bank of N.T. Butterfield & Son Limited ("Butterfield" or the "Bank") (BSX: NTB.BH; NYSE: NTB) today announced financial results for the quarter ended March 31, 2024. Net income for the first quarter of 2024 was $53.4 million, or $1.13 per...

at 16:35
Crescent Energy Company today announced plans to host a conference call and webcast at 10 a.m. CT, on Tuesday, May 7, 2024 to discuss its first quarter 2024 financial and operating results. The Company plans to release results after market close on...

at 16:35
Oregon Pacific Bancorp (ORPB), the holding company of Oregon Pacific Bank, today reported financial results for the first quarter ended, March 31, 2024. Highlights: First quarter net income of $1.6 million; $0.22 per diluted share. Quarterly...

at 16:35
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets...



News published on and distributed by: